| 1 |
Desheva Y, Petkova N, Losev I, Guzhov D, Go A, Chao YC, Tsai CH. Establishment of a Pseudovirus Platform for Neuraminidase Inhibiting Antibody Analysis. Int J Mol Sci 2023;24. [PMID: 36768700 DOI: 10.3390/ijms24032376] [Reference Citation Analysis]
|
| 2 |
D’apice L, Trovato M, Gramigna G, Colavita F, Francalancia M, Matusali G, Meschi S, Lapa D, Bettini A, Mizzoni K, Aurisicchio L, Di Caro A, Castilletti C, De Berardinis P. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. Front Immunol 2022;13:981693. [DOI: 10.3389/fimmu.2022.981693] [Reference Citation Analysis]
|
| 3 |
Takeuchi Y. Special Issue "Lentiviral Vectors". Viruses 2022;14:1492. [PMID: 35891475 DOI: 10.3390/v14071492] [Reference Citation Analysis]
|
| 4 |
Chmielewska AM, Czarnota A, Bieńkowska-Szewczyk K, Grzyb K. Immune response against SARS-CoV-2 variants: the role of neutralization assays. NPJ Vaccines 2021;6:142. [PMID: 34845231 DOI: 10.1038/s41541-021-00404-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 5 |
Schuh W, Baus L, Steinmetz T, Schulz SR, Weckwerth L, Roth E, Hauke M, Krause S, Morhart P, Rauh M, Hoffmann M, Vesper N, Reth M, Schneider H, Jäck HM, Mielenz D. A surrogate cell-based SARS-CoV-2 spike blocking assay. Eur J Immunol 2021;51:2665-76. [PMID: 34547822 DOI: 10.1002/eji.202149302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 6 |
Bentley EM, Richardson S, Derveni M, Rijal P, Townsend AR, Heeney JL, Mattiuzzo G, Wright E. Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay. Trop Med Infect Dis 2021;6:155. [PMID: 34449756 DOI: 10.3390/tropicalmed6030155] [Reference Citation Analysis]
|
| 7 |
Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Gene Therapy in Hemophilia: Recent Advances. Int J Mol Sci 2021;22:7647. [PMID: 34299267 DOI: 10.3390/ijms22147647] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 8 |
Del Rosario JMM, da Costa KAS, Asbach B, Ferrara F, Ferrari M, Wells DA, Mann GS, Ameh VO, Sabeta CT, Banyard AC, Kinsley R, Scott SD, Wagner R, Heeney JL, Carnell GW, Temperton NJ. Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection. Vaccines (Basel) 2021;9:741. [PMID: 34358157 DOI: 10.3390/vaccines9070741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Del Rosario JMM, da Costa KA, Asbach B, Ferrara F, Ferrari M, Wells DA, Mann GS, Ameh VO, Sabeta CT, Banyard AC, Kinsley R, Scott SD, Wagner R, Heeney JL, Carnell GW, Temperton NJ. Establishment of pan-Influenza A (H1-H18) and pan-Influenza B (pre-split, Vic/Yam) Pseudotype Libraries for efficient vaccine antigen selection.. [DOI: 10.1101/2021.05.20.444964] [Reference Citation Analysis]
|
| 10 |
Bisgin A, Sanlioglu AD, Eksi YE, Griffith TS, Sanlioglu S. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Hum Gene Ther 2021;32:541-62. [PMID: 33858231 DOI: 10.1089/hum.2021.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
